| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 203 companies in the Health Care Equipment & Supplies industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | AORT Artivion, Inc. | Horton Amy48 | VP, Chief Accounting Officer | Sell | 3,323 | $27.31 | $90,737.52 | -0.6% | +4.9% | +26.9% | |
| Feb 24, 2025 | AORT Artivion, Inc. | Stanton Marshall S. | SVP, Clinical &MD Affair | Sell | 4,687 | $27.31 | $127,983.22 | -1.4% | +4.9% | +26.9% | |
| Feb 24, 2025 | AORT Artivion, Inc. | Davis John E | Chief Commercial Officer | Sell | 6,457 | $27.31 | $176,314.84 | -1.0% | +4.9% | +26.9% | |
| Feb 24, 2025 | AORT Artivion, Inc. | MacKin James P53 | President &CEO | Sell | 42,156 | $27.31 | $1,151,111.74 | -1.5% | +4.9% | +26.9% | |
| Feb 24, 2025 | AORT Artivion, Inc. | Berry Lance A | Executive VP, CFO | Sell | 3,259 | $27.31 | $88,990.25 | -4.1% | +4.9% | +26.9% | |
| Feb 24, 2025 | AORT Artivion, Inc. | Holloway Jean F49 | SVP, General Counsel | Sell | 5,335 | $27.31 | $145,677.51 | -0.9% | +4.9% | +26.9% | |
| Feb 24, 2025 | STME Stimcell Energetics Inc. | Jeffs Richard | 10% Owner | Buy | 19,399 | $0.17 | $3,309.80 | +0.6% | - | - | |
| Feb 24, 2025 | TCMD Tactile Systems Technology Inc | Reuvers Daniel L.67 | Director | Sell | 10,938 | $14.55 | $159,146.81 | -4.3% | -34.5% | +92.3% | |
| Feb 24, 2025 | TCMD Tactile Systems Technology Inc | Birkemeyer Elaine M. | Chief Financial Officer | Sell | 3,778 | $14.70 | $55,538.11 | -3.5% | -34.5% | +92.3% | |
| Feb 24, 2025 | ELMD Electromed, Inc. | Summers Andrew79 | Director | Sell | 111,475 | $27.99 | $3,120,226.23 | -6.3% | -24.7% | -14.2% | |
| Feb 24, 2025 | TCMD Tactile Systems Technology Inc | Burns Kristie60 | Sr. VP Mktg &Clinical Affairs | Sell | 4,830 | $14.65 | $70,752.74 | -5.4% | -34.5% | +92.3% | |
| Feb 21, 2025 | NPCE Neuropace Inc | Morrell Martha59 | Chief Medical Officer | Sell | 78,334 | $13.72 | $1,074,844.31 | -48.9% | +29.8% | +4.1% | |
| Feb 21, 2025 | BSX Boston Scientific Corp | Brown Vance R | SVP, GC And Corp. Secretary | Sell | 4,826 | $104.64 | $504,992.64 | -9.5% | +0.0% | -28.6% | |
| Feb 20, 2025 | RBOT Vicarious Surgical Inc. | Sachs Adam David84 | CEO | Sell | 943 | $14.53 | $13,704.81 | -1.8% | -51.3% | -84.5% | |
| Feb 20, 2025 | RCEL Avita Medical, Inc. | McNamara Robert | Director | Buy | 10,000 | $10.09 | $100,900.00 | +28.0% | -34.5% | -51.9% | |
| Feb 20, 2025 | SSII Ss Innovations International, Inc. | Moll Frederic H | Director, 10% Owner | Buy | 3,645,224 | $1.37 | $5,001,247.33 | +56.8% | - | - | |
| Feb 20, 2025 | LUNG Pulmonx Corp | French Glendon E. III84 | Director | Sell | 55,453 | $8.28 | $459,085.96 | -2.7% | -64.2% | -82.9% | |
| Feb 20, 2025 | NPCE Neuropace Inc | Kck Ltd. | 10% Owner | Sell | 5,270,845 | $9.40 | $49,545,943.00 | -100% | +27.4% | +0.8% | |
| Feb 20, 2025 | RBOT Vicarious Surgical Inc. | Khalifa Sammy84 | Chief Technology Officer | Sell | 754 | $14.53 | $10,956.00 | -2.0% | -51.3% | -84.5% | |
| Feb 20, 2025 | RCEL Avita Medical, Inc. | O'Toole David D47 | CFO | Buy | 1,000 | $9.90 | $9,900.00 | +4.0% | -34.5% | -51.9% | |
| Feb 20, 2025 | SSII Ss Innovations International, Inc. | Srivastava Sudhir | Chairman And CEO | Sell | 3,645,224 | $1.37 | $5,001,247.33 | -3.8% | - | - | |
| Feb 19, 2025 | RCEL Avita Medical, Inc. | O'Toole David D47 | CFO | Buy | 1,000 | $10.25 | $10,250.00 | +4.2% | -34.4% | -57.1% | |
| Feb 19, 2025 | BSX Boston Scientific Corp | Mirviss Jeffrey B.45 | EVP&Pres, Periph Intervent | Sell | 1,510 | $105.35 | $159,078.50 | -4.4% | +0.8% | -28.3% | |
| Feb 19, 2025 | XAIR Beyond Air, Inc. | Gaul Michael A. | Chief Operating Officer | Buy | 6,000 | $0.38 | $2,293.80 | +6.8% | -49.2% | -85.6% | |
| Feb 19, 2025 | BSX Boston Scientific Corp | Brennan Daniel J.47 | EVP And CFO | Sell | 84,863 | $105.10 | $8,919,295.52 | -10.7% | +0.8% | -28.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.